Erythropoietin-mediated cardioprotection in hearts subjected to ischemia reperfusion

J Mol Endocrinol. 2023 Sep 13;71(3):e230076. doi: 10.1530/JME-23-0076. Print 2023 Oct 1.

Abstract

Several studies provide evidence that erythropoietin (EPO) could play an important role in the recovery of the heart subjected to ischemia-reperfusion. In this regard, it has been suggested that EPO could be involved in protein kinase B (Akt) activation as a cell survival protein. The aim of the present study was to investigate the effects of EPO on the Akt/glycogen synthase kinase 3 beta (GSK-3β) pathway in the presence or absence of wortmannin (W, Akt inhibitor) and its relationship with mitochondrial morphology and function preservation in ischemic-reperfused rat hearts. EPO improved the functional recovery of the heart subjected to ischemia-reperfusion, reduced the release of CK and the infarct size, and promoted preservation of the mitochondrial structure. Moreover, it reduced tissue lactate content and preserved glycogen in order to prevent ischemia. The results showed greater Akt activation, accompanied by preservation of swelling and mitochondrial calcium retention capacity, as well as an increase in ATP synthesis capacity. These results were accompanied by an inhibition of GSK-3β, suggesting regulation of Akt on the opening of the mitochondrial permeability transition pore. All these beneficial effects exerted by acute treatment with EPO were prevented by W. The present study provided novel evidence that EPO not only enhances intrinsic activation of Akt during myocardial ischemia-reperfusion but also promotes GSK-3β inhibition, contributing to mitochondrial structure and function preservation.

Keywords: Akt; GSK-3β; MPTP; erythropoietin; heart; ischemia–reperfusion; wortmannin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cardiotonic Agents* / pharmacology
  • Erythropoietin* / pharmacology
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Heart* / drug effects
  • Ischemia
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt* / metabolism
  • Rats
  • Reperfusion Injury*

Substances

  • Erythropoietin
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt
  • Cardiotonic Agents